A Phase 1 Study of MEDI1873 (GITR Agonist) in Adult Subjects With Select Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2018
At a glance
- Drugs MEDI 1873 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors MedImmune
- 26 Feb 2018 Planned End Date changed from 30 Mar 2021 to 22 Jan 2021.
- 26 Feb 2018 Planned primary completion date changed from 1 Jan 2019 to 28 Nov 2018.
- 26 Feb 2018 Status changed from recruiting to active, no longer recruiting.